1. |
Bonner R, Albajrami O, Hudspeth J, et al. Diabetic kidney disease. Prim Care, 2020, 47(4): 645-659.
|
2. |
刘彦玲, 张丛, 王强, 等. 糖尿病肾病代谢组学差异代谢物的研究进展. 药物评价研究, 2019, 42(1): 187-193.
|
3. |
Anders HJ, Huber TB, Isermann B, et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol, 2018, 14(6): 361-377.
|
4. |
Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J, 2022, 46(2): 181-197.
|
5. |
Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric diabetic kidney disease. Clin Exp Nephrol, 2020, 24(7): 573-581.
|
6. |
Zhang S, Li X, Luo H, et al. Role of aromatic amino acids in pathogeneses of diabetic nephropathy in Chinese patients with type 2 diabetes. J Diabetes Complications, 2020, 34(10): 107667.
|
7. |
Qi Q, Li J, Yu B, et al. Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies. Gut, 2022, 71(6): 1095-1105.
|
8. |
Zhang F, Guo R, Cui W, et al. Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy. Ren Fail, 2021, 43(1): 980-992.
|
9. |
Jin Q, Ma RCW. Metabolomics in diabetes and diabetic complications: insights from epidemiological studies. Cells, 2021, 10(11): 2832.
|
10. |
Wu MH, Lin CN, Chiu DT, et al. Kynurenine/tryptophan ratio predicts angiotensin receptor blocker responsiveness in patients with diabetic kidney disease. Diagnostics (Basel), 2020, 10(4): 207.
|
11. |
Liu S, Li L, Lou P, et al. Elevated branched-chain α-keto acids exacerbate macrophage oxidative stress and chronic inflammatory damage in type 2 diabetes mellitus. Free Radic Biol Med, 2021, 175: 141-154.
|
12. |
Zhang X, Liu D, He Y, et al. Branched chain amino acids protects rat mesangial cells from high glucose by modulating TGF-β1 and BMP-7. Diabetes Metab Syndr Obes, 2019, 12: 2433-2440.
|
13. |
Zhou C, Zhang Q, Lu L, et al. Metabolomic profiling of amino acids in human plasma distinguishes diabetic kidney disease from type 2 diabetes mellitus. Front Med (Lausanne), 2021, 8: 765873.
|
14. |
Saleem T, Dahpy M, Ezzat G, et al. The profile of plasma free amino acids in type 2 diabetes mellitus with insulin resistance: association with microalbuminuria and macroalbuminuria. Appl Biochem Biotechnol, 2019, 188(3): 854-867.
|
15. |
Mbhele T, Tanyanyiwa DM, Moepya RJ, et al. Relationship between amino acid ratios and decline in estimated glomerular filtration rate in diabetic and non-diabetic patients in South Africa. Afr J Lab Med, 2021, 10(1): 1398.
|
16. |
Luo Q, Liang W, Zhang Z, et al. Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism. Metabolism, 2022, 134: 155245.
|
17. |
Cao P, Huang B, Hong M, et al. Association of amino acids related to urea cycle with risk of diabetic nephropathy in two independent cross-sectional studies of Chinese adults. Front Endocrinol (Lausanne), 2022, 13: 983747.
|
18. |
Abdelsattar S, Kasemy ZA, Elsayed M, et al. Targeted metabolomics as a tool for the diagnosis of kidney disease in type Ⅱ diabetes mellitus. Br J Biomed Sci, 2021, 78(4): 184-190.
|
19. |
Gao Z, Chen X. Fatty acid β-oxidation in kidney diseases: perspectives on pathophysiological mechanisms and therapeutic opportunities. Front Pharmacol, 2022, 13: 805281.
|
20. |
Zhang H, Zuo JJ, Dong SS, et al. Identification of potential serum metabolic biomarkers of diabetic kidney disease: a widely targeted metabolomics study. J Diabetes Res, 2020, 2020: 3049098.
|
21. |
Feng Q, Li Y, Yang Y, et al. Urine metabolomics analysis in patients with normoalbuminuric diabetic kidney disease. Front Physiol, 2020, 11: 578799.
|
22. |
Fijałkowski M, Stępniewska J, Domański M, et al. The role of eicosanoids in renal diseases - potential therapeutic possibilities. Acta Biochim Pol, 2018, 65(4): 479-486.
|
23. |
Mota-Zamorano S, Robles NR, Lopez-Gomez J, et al. Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease. EXCLI J, 2021, 20: 698-708.
|
24. |
Morita Y, Kurano M, Sakai E, et al. Simultaneous analyses of urinary eicosanoids and related mediators identified tetranor-prostaglandin E metabolite as a novel biomarker of diabetic nephropathy. J Lipid Res, 2021, 62: 100120.
|
25. |
Kaewin S, Changsorn K, Sungkaworn T, et al. Fungus-derived 3-hydroxyterphenyllin and candidusin a ameliorate palmitic acid-induced human podocyte injury via anti-oxidative and anti-apoptotic mechanisms. Molecules, 2022, 27(7): 2109.
|
26. |
Chang W, Hatch GM, Wang Y, et al. The relationship between phospholipids and insulin resistance: from clinical to experimental studies. J Cell Mol Med, 2019, 23(2): 702-710.
|
27. |
Mitrofanova A, Fontanella AM, Merscher S, et al. Lipid deposition and metaflammation in diabetic kidney disease. Curr Opin Pharmacol, 2020, 55: 60-72.
|
28. |
Yoshioka K, Hirakawa Y, Kurano M, et al. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. Kidney Int, 2022, 101(3): 510-526.
|
29. |
Huang J, Covic M, Huth C, et al. Validation of candidate phospholipid biomarkers of chronic kidney disease in hyperglycemic individuals and their organ-specific exploration in leptin receptor-deficient db/db mouse. Metabolites, 2021, 11(2): 89.
|
30. |
Mu X, Yang M, Ling P, et al. Acylcarnitines: can they be biomarkers of diabetic nephropathy?. Diabetes Metab Syndr Obes, 2022, 15: 247-256.
|
31. |
Esmati P, Najjar N, Emamgholipour S, et al. Mass spectrometry with derivatization method for concurrent measurement of amino acids and acylcarnitines in plasma of diabetic type 2 patients with diabetic nephropathy. J Diabetes Metab Disord, 2021, 20(1): 591-599.
|
32. |
Afshinnia F, Nair V, Lin J, et al. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight, 2019, 4(21): e130317.
|
33. |
Lunyera J, Diamantidis CJ, Bosworth HB, et al. Urine tricarboxylic acid cycle signatures of early-stage diabetic kidney disease. Metabolomics, 2021, 18(1): 5.
|
34. |
Tang X, You J, Liu D, et al. 5-hydroxyhexanoic acid predicts early renal functional decline in type 2 diabetes patients with microalbuminuria. Kidney Blood Press Res, 2019, 44(2): 245-263.
|
35. |
郑丹娜, 何强. 尿液标志物在糖尿病肾病早期诊断中的研究进展. 中国中西医结合肾病杂志, 2020, 21(6): 553-555.
|
36. |
Sanchez M, Roussel R, Hadjadj S, et al. Plasma concentrations of 8-hydroxy-2’-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia, 2018, 61(4): 977-984.
|
37. |
Peng X, Wang X, Shao X, et al. Serum metabolomics benefits discrimination kidney disease development in type 2 diabetes patients. Front Med (Lausanne), 2022, 9: 819311.
|
38. |
Linnan B, Yanzhe W, Ling Z, et al. In situ metabolomics of metabolic reprogramming involved in a mouse model of type 2 diabetic kidney disease. Front Physiol, 2021, 12: 779683.
|
39. |
Tao S, Zheng W, Liu Y, et al. Analysis of serum metabolomics among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls. RSC Adv, 2019, 9(33): 18713-18719.
|